Butyrolactone‐I, an efficient α‐glucosidase inhibitor, improves type 2 diabetes with potent TNF‐α–lowering properties through modulating gut microbiota in db/db mice-Reference-Cited by-同舟云学术

Butyrolactone‐I, an efficient α‐glucosidase inhibitor, improves type 2 diabetes with potent TNF‐α–lowering properties through modulating gut microbiota in db/db mice

Published:2019-08-26 Issue:11 Volume:33 Page:12616-12629
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Wu Wei¹,Liu Liyun¹,Zhu Hongrui²,Sun Yating¹,Wu Ying¹,Liao Hongze¹,Gui Yuhan¹,Li Lei¹,Liu Lei¹,Sun Fan¹,Lin Houwen¹

Affiliation:

1. State Key Laboratory of Oncogenes and Related GenesDepartment of PharmacyResearch Center for Marine Drugs, School of Medicine, Ren Ji Hospital, Shanghai Jiao Tong UniversityShanghaiChina

2. School of Life Sciences and Biopharmaceutical Sciences, Shenyang Pharmaceutical UniversityLiaoningChina

Funder

National Basic Research Program of China

National Natural Science Foundation of China

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.201901061R

Reference56 articles.

1. Global estimates of the prevalence of diabetes for 2010 and 2030